Hazard Information
Uses
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2].
in vivo
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].
| Animal Model: | Nude mice inoculated with SK-N-FI tumor cells[2] |
| Dosage: | 0.04 or 0.1 mg/mouse |
| Administration: | Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days |
| Result: | Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] |
| Dosage: | 0.02, 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days |
| Result: | Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: | Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2] |
| Dosage: | 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days |
| Result: | Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model. Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: | Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2] |
| Dosage: | 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks |
| Result: | Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft. Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] |
| Dosage: | 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation |
| Result: | Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
References
[1] Anderson PM, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. DOI:10.1002/pbc.26087
[2] Wang Y, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010 Feb;9(2):410-8. DOI:10.1158/1535-7163.MCT-09-0555
[2] Wang Y, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010 Feb;9(2):410-8. DOI:10.1158/1535-7163.MCT-09-0555
Supplier
Shanghai YuanYe Biotechnology Co., Ltd.
Telephone 13636370518
Websitehttps://www.shyuanye.com
ShangHai Biochempartner Co.,Ltd
Telephone177-54423994 17754423994
Websitehttps://www.biochempartner.com
Guangzhou Hongyuan Chemical Co.,Ltd
Telephone 15817493340
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList1222417/0_EN.htm
Wuhan Chemstan Biotechnology Co., Ltd.
Telephone027-65317797 15926423062
Websitehttp://www.chemstan.com/
Beijing Jin Ming Biotechnology Co., Ltd.
Telephone010-60605840
Websitehttp://www.jm-bio.com/
TargetMol Chemicals Inc.
Telephone4008200310 15002144251
Websitehttps://www.targetmol.cn/
Biolab Reagents
Telephone027-65279366 18108604356
Websitehttps://www.biolabreagent.com/
Wuhan Jingkangen Biomedical Technology Co., Ltd
Telephone13720134139 086-15871494362 13720134139
Websitehttps://www.jknbiochem.com
Shanghai Yifei Biotechnology Co. , Ltd.
Telephone021-65675885 18964387627
Websitehttp://www.efebio.com
Wuhan Acumen Bio-Technology Co.,ltd
Telephone027-027-16602739303 16602739303
Websitehttp://www.yjybiochem.com/
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
Telephone4000862158 18117107507
Websitehttps://www.med-life.cn/
Changsha Fuzhen Biotechnology Co.，LTD
Telephone15111215862 18229892877
Websitehttps://www.chemicalbook.com/supplier/25777903/
Olix ( Hubei) Pharmaceutical Technology Co., Ltd
Telephone17316404525 17316404525
Websitehttps://www.olix.cn
Wanxin Biotechnology (Jiaxing) Co., LTD
Telephone0573-83568680 18057391398
Website
Atagenix Laboratories
Telephone027-87008169 17762441161
Websitehttps://www.abinscience.com/
AntibodySystem Laboratories SAS
Telephone 33175446423
Websitehttp://www.antibodysystem.com
Biosynth Biological Technology (Suzhou) Co Ltd
Telephone 51288865780
Websitehttp://www.biosynth.com
Cell Sciences
Telephone 9785721070
Websitehttp://www.cellsciences.com
1of4
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine